Saturday, 20 August 2022

Era of magnesium for orthopaedics and traumatology begins in India

08 October 2021 | News

Patient potential already more than three times as large as the entire EU

image credit- Syntellix

image credit- Syntellix

The Central Drugs Standard Control Organisation (CDSCO) has granted German firm Syntellix the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market.

In one fell swoop, this increases global market access and the amount of potential patients who can be treated with the company's MAGNEZIX® implants by an additional 1.38 billion to now 3.8 billion people. 

The game-changer market of India, with its exceptionally good doctors and in many cases ultra-modern hospitals, plays a decisive role in the global substitution of conventional implant technologies in favour of the MAGNEZIX® platform technology.

In addition, India is ideally suited for collecting further clinical data and conducting clinical trials and will also contribute significantly to the development of new, additional Syntellix products.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account